EPS for Neovasc Inc. (NVCN) Expected At $-0.01

March 16, 2018 - By Adrian Erickson

 EPS for Neovasc Inc. (NVCN) Expected At $ 0.01

Analysts expect Neovasc Inc. (NASDAQ:NVCN) to report $-0.01 EPS on March, 22.They anticipate $0.48 EPS change or 102.13 % from last quarter’s $0.47 EPS. After having $-0.06 EPS previously, Neovasc Inc.’s analysts see -83.33 % EPS growth. The stock decreased 16.97% or $0.0227 during the last trading session, reaching $0.1111. About 63.90 million shares traded or 574.67% up from the average. Neovasc Inc. (NASDAQ:NVCN) has declined 19.02% since March 16, 2017 and is downtrending. It has underperformed by 35.72% the S&P500.

Neovasc Inc. (NASDAQ:NVCN) Ratings Coverage

Among 3 analysts covering Neovasc (NASDAQ:NVCN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Neovasc had 7 analyst reports since August 12, 2015 according to SRatingsIntel. As per Wednesday, August 26, the company rating was downgraded by Zacks. The rating was downgraded by Zacks on Wednesday, August 12 to “Buy”. The rating was initiated by JMP Securities with “Market Outperform” on Wednesday, October 7. Ladenburg Thalmann initiated it with “Buy” rating and $9.25 target in Thursday, December 10 report. The company was maintained on Tuesday, August 25 by Canaccord Genuity. Ladenburg Thalmann downgraded the stock to “Neutral” rating in Friday, May 20 report.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $14.49 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It has a 0.44 P/E ratio. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.